You can buy or sell Enanta and other stocks, options, ETFs, and crypto commission-free!
Enanta Pharmaceuticals, Inc. Common Stock, also called Enanta, is a research and development-focused biotechnology company. Read More It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
52 Week High
52 Week Low
Research And Development
Present Performance: Enanta Pharmaceuticals (NASDAQ: ENTA)
Enanta Pharmaceuticals is in the biotechnology industry and is part of the healthcare sector. The company CEO is Jay R. Luly. Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach and drug discovery capabilities to develop its products. Previous Intraday Trading Performance: The ENTA stock showed a previous change of -6.45% with an open at 96.99 and a close of 97.08....
Seeking AlphaMar 18
Enanta Pharmaceuticals (ENTA) Investor Presentation - Slideshow
The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with this event. 1 33 Click to enlarge Notes:...
Simply Wall StMar 14
Introducing Enanta Pharmaceuticals (NASDAQ:ENTA), The Stock That Zoomed 279% In The Last Three Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. To wit, the Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) share price has flown 279% in the last three years. Most would be happy with that. It’s also good to see the share price up 42% over the last quarter. See our latest analysis for Enanta Pharmaceuticals While markets are a powerful pricing mechanism, share pr...
Available May 7, After Hours